Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055222 | 0.84 | ABL1 (0.52) | MAP3K5KMT2AMEN1ABL1RIN1 | |
| SCHEMBL16393091 | 0.81 | MEN1 (0.58) | KMT2AMEN1ABL1RIN1NPC1 | |
| SCHEMBL10001691 | 0.81 | KMT2A (0.58) | KMT2AMEN1ABL1RIN1NPC1 | |
| SCHEMBL15763376 | 0.81 | MAPT (0.50) | MAP3K5ABL1MAPTHTTLMNA | |
| SCHEMBL27057456 | 0.80 | KMT2A (0.50) | MAP3K5KMT2AMEN1ABL1RIN1 | |
| SCHEMBL9569421 | 0.80 | MEN1 (0.60) | KMT2AMEN1ABL1RIN1NPC1 | |
| SCHEMBL22666438 | 0.80 | KMT2A (0.44) | MAP3K5KMT2AMEN1ABL1RIN1 | |
| SCHEMBL18825323 | 0.78 | MEN1 (0.58) | KMT2AMEN1ABL1RIN1NPC1 | |
| SCHEMBL16639110 | 0.78 | POLB (0.45) | MAP3K5KMT2AMEN1ABL1RIN1 | |
| SCHEMBL16662393 | 0.78 | KMT2A (0.54) | KMT2AMEN1ABL1RIN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3672601-B1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | SAREPTA THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023131170-A1 | DOUBLE-STRANDED RNA HAVING NUCLEOTIDE ANALOG | 大睿生物医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11384105-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11230565-B2 | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10961262-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10947533-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-8030467-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100184966-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7750131-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7666854-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666854-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090192302-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7547684-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | MAP3K5 3472/4885KMT2A 2433/4885MEN1 1327/4885 |
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | MAP3K5 4534/4885KMT2A 1178/4885MEN1 1215/4885 |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | MAP3K5 4534/4885KMT2A 1178/4885MEN1 1215/4885 |
| US-10961262-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | PPIP5K2, MTAP, RNGTT | MAP3K5 2115/4885KMT2A 3884/4885MEN1 1249/4885 |
| US-11230565-B2 | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry | RNASEH1, RNASE1, PMM2 | MAP3K5 4292/4885KMT2A 996/4885MEN1 627/4885 |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | PPIP5K2, MTAP, RNGTT | MAP3K5 2115/4885KMT2A 3884/4885MEN1 1249/4885 |
| US-20100184966-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | MAP3K5 4540/4885KMT2A 1432/4885MEN1 2680/4885 |
| US-20090192302-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | MAP3K5 4540/4885KMT2A 1432/4885MEN1 2680/4885 |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | MAP3K5 4540/4885KMT2A 1432/4885MEN1 2680/4885 |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | PCBP1, RNGTT, PHAX | MAP3K5 4449/4885KMT2A 3693/4885MEN1 1571/4885 |
| US-11384105-B2 | Processes for preparing oligomers | NOP2, RNGTT, PCBP1 | MAP3K5 3827/4885KMT2A 3626/4885MEN1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.